Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

NCT04055753 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Doxil
DRUG: Doxorubicin

Sponsor

Fox Chase Cancer Center